Saving lives – with and beyond dialysis
Doubling up on a second chance
A robot at the operating table
Midwife, a dream job
My 50 years of dialysis
An almost irreplaceable organ
Living life to the fullest with dialysis
Growing up with parenteral nutrition
The History of Dialysis
Serving patients in Swaziland
"I want to help others, so they won’t give up"
From a local pharmacy to a global corporation
Group Outlook 2021
Based on the Group’s good Q3/21 results and the progress to improve Group-wide efficiencies, Fresenius raises its sales guidance1 and improves its earnings guidance2,3. The Company now projects constant currency sales1 to grow in a mid single-digit range in FY/21. Previously, the Company projected sales1 growth in a low-to-mid single-digit percentage range in constant currency. Earnings2,3 growth in constant currency is now expected to be around the top-end of the low single-digit percentage range.
Implicitly, net income2 for the Group excluding Fresenius Medical Care is now expected to grow in a low double-digit percentage range in constant currency. Previously, Fresenius expected high single-digit percentage growth in constant currency.
The guidance implies ongoing COVID-19 related headwinds, primarily at Fresenius Medical Care, and increasingly noticeable cost inflation across selected markets in Q4/21. It also reflects negative pricing effects related to tender activity at Fresenius Kabi in China.
COVID-19 assumptions for guidance FY/21
Negative COVID-19 effects at Fresenius have increased sequentially in Q3/21, driven by significant excess patient mortality at Fresenius Medical Care. Fresenius expects also Q4/21 to be impacted by COVID-19 effects. Meaningfully rising COVID-19 case numbers, the further evolution of virus mutations as well as stalling vaccination progress could impact Fresenius’ ability to achieve its FY/21 guidance. Additionally, Fresenius expects headwinds from cost inflation including rising commodity and shipping prices, increasing energy costs, as well as supply chain constraints in Q4/21. Hence, Fresenius remains vigilant.
Whilst the risk of renewed far-reaching containment measures in one or more of Fresenius’ major markets cannot be excluded, it now appears unlikely. Any resulting significant and direct impact on the health care sector without appropriate compensation is not reflected in the Group’s FY / 21 guidance. These assumptions are subject to considerable uncertainty.
1 Net income attributable to shareholders of Fresenius SE & Co. KGaA
2 FY / 20 base: €1,796 million, before special items; FY / 21: before special items
3 FY / 20 base: €36,277 million
